(Q42682897)

4 November 2017

0 references

Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue (English)

1 reference

4 November 2017

1 reference

Bruzzi P

1

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

4 November 2017

1 reference

4 November 2017

316

1 reference

4 November 2017

7139

1 reference

4 November 2017

1181-1182

1 reference

Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial

4 November 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1112979

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

27 May 2018

1 reference

12 December 2020

Breast cancer trial stopped early

1 reference

12 December 2020

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

12 December 2020

Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women

1 reference

12 December 2020

10.1136/BMJ.316.7139.1181

Identifiers

DOI

1 reference

release_i6m2jqchjneythyaq22fpj3g44

4 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/i6m2jqchjneythyaq22fpj3g44

24 November 2022

mapped directly with Wikidata item

1 reference

4 November 2017

PubMed publication ID

9552991

1 reference